Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Cydy in Nash!

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Dec 02, 2020 11:21am

87 Views

Post# 32017917

RE:RE:Cydy in Nash!

It's targeted against CCR5, the same as another drug Mariviroc. Mariviroc is actually also being tested in all the same indications as cydy's drug. Hiv entry, cancer, Covid and Nash. The company are certainly gung-ho about chasing these different indications but I don't think completely blindly. All you can really say is they seem to be the opposite end of the conservatism scale to THTX. The Oslo site end on many scales probably, go to their website and the first thing you see is a wall of promotion.